
News|Articles|November 1, 2004
New indications: Aripiprazole
Atypical antipsychotic approved for acute bipolar mania This atypical antipsychotic is believed to exert its effect through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. An expanded indication for aripiprazole was approved on September 29, 2004, to include the treatment of acute manic and mixed episodes associated with Bipolar Disorder.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Schizophrenia, Bipolar Disorder, and MDD Linked to Increased Risk for Developing Long COVID
2
MHE Week in Review – White House GLP-1 Deal, AI Spots Cancer Risk and More
3
Health Plans Beware: Keep Contract Language Tight If Your PBM Wants Rebate Guarantees Renegotiated Because of the IRA and Biosimilars | AMCP Nexus 2025
4
PBMs Make a Case for the GLP-1 Teeter Totter: Up on the Pharmacy Benefit, Down on the Medical One | AMCP Nexus 2025
5

















































